Literature DB >> 8381154

Production and characterization of an Mls-1-specific monoclonal antibody.

N Mohan1, D Mottershead, M Subramanyam, U Beutner, B T Huber.   

Abstract

Superantigens (SAGs) represent a new class of antigens, characterized as T cell receptor (TCR) V beta-reactive elements. Bacterial toxins constitute the major group of exogenous SAGs, while the mouse mammary tumor virus (MMTV)-encoded Mls molecules represent the endogenous SAGs. Mls-1 is the prototype of the latter SAGs, because it elicits a very potent T cell stimulatory response in vitro in unprimed T cells expressing the TCR V beta 6 or 8.1 chains. In vivo, Mls-1 causes deletion of immature T cells bearing the V beta 6, 7, 8.1, or 9 chains. Although Mls-1 was functionally discovered > 20 yr ago, it has not been possible to raise antibodies against this molecule. We have previously cloned and sequenced the Mtv-7 sag gene, which encodes Mls-1. Sequence comparisons with other MMTV sag genes suggested that the polymorphic 3' end encodes the TCR V beta specificity of these SAGs. We have, therefore, immunized hamsters with a 14-amino acid peptide from the deduced COOH-terminal sequence of the Mtv-7 sag gene. We describe here the production of a monoclonal antibody (mAb), 3B12, which is peptide specific and reacts with a recombinant baculovirus product of Mtv-7 sag. This mAb blocks Mls-1-specific T cell recognition and detects the Mls-1 protein on the surface of the B cell hybridoma LBB.A, but not on LBB.11, which is an Mtv-7 loss variant of LBB.A. Transfection of the Mtv-7 sag gene into LBB.11 renders this cell functionally Mls-1+ as well as positive for 3B12 binding, confirming the specificity of this mAb. It is well documented that B cells and CD8+ T cells express T cell stimulatory Mls-1 determinants, and we show here that this functional profile correlates with the expression of MMTV-specific mRNA. However, primary lymphocytes derived from Mls-1+ mice do not stain with 3B12, even after in vitro activation with mitogens or phorbol ester.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8381154      PMCID: PMC2190914          DOI: 10.1084/jem.177.2.351

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  34 in total

Review 1.  T-cell responses to Mls and to bacterial proteins that mimic its behavior.

Authors:  C A Janeway; J Yagi; P J Conrad; M E Katz; B Jones; S Vroegop; S Buxser
Journal:  Immunol Rev       Date:  1989-02       Impact factor: 12.988

2.  An improvement of the single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  C Puissant; L M Houdebine
Journal:  Biotechniques       Date:  1990-02       Impact factor: 1.993

3.  Macrophages and T cells do not express Mlsa determinants.

Authors:  I J Molina; N A Cannon; R Hyman; B T Huber
Journal:  J Immunol       Date:  1989-07-01       Impact factor: 5.422

4.  A T cell receptor V beta segment that imparts reactivity to a class II major histocompatibility complex product.

Authors:  J W Kappler; T Wade; J White; E Kushnir; M Blackman; J Bill; N Roehm; P Marrack
Journal:  Cell       Date:  1987-04-24       Impact factor: 41.582

5.  Relationship of B cell Fc receptors to T cell recognition of Mls antigen.

Authors:  J F Nicolas; D Wegmann; P Lebrun; D Kaiserlian; J Tovey; A L Glasebrook
Journal:  Eur J Immunol       Date:  1987-11       Impact factor: 5.532

6.  A third T-cell receptor beta-chain variable region gene encodes reactivity to Mls-1a gene products.

Authors:  M P Happ; D L Woodland; E Palmer
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

7.  Characterization of a rat monoclonal antibody specific for a determinant encoded by the V beta 7 gene segment. Depletion of V beta 7+ T cells in mice with Mls-1a haplotype.

Authors:  C Y Okada; B Holzmann; C Guidos; E Palmer; I L Weissman
Journal:  J Immunol       Date:  1990-05-01       Impact factor: 5.422

8.  Control of lymphokine expression in T helper 2 cells.

Authors:  E Muñoz; A Zubiaga; D Olson; B T Huber
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

9.  The V beta-specific superantigen staphylococcal enterotoxin B: stimulation of mature T cells and clonal deletion in neonatal mice.

Authors:  J White; A Herman; A M Pullen; R Kubo; J W Kappler; P Marrack
Journal:  Cell       Date:  1989-01-13       Impact factor: 41.582

10.  Restricted tissue distribution of Mlsa determinants. Stimulation of Mlsa-reactive T cells by B cells but not by dendritic cells or macrophages.

Authors:  S R Webb; A Okamoto; Y Ron; J Sprent
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

View more
  6 in total

1.  New superantigen specificity created by two amino acid replacements.

Authors:  O A Rosenwasser; S Fairchild; K Tomonari
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

2.  Tcrb-V12-specific superantigens encoded by mouse mammary tumor proviruses.

Authors:  K Tomonari
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

3.  Negative-acting factor and superantigen are separable activities of the mouse mammary tumor virus long terminal repeat.

Authors:  S Wintersperger; B Salmons; T Miethke; V Erfle; H Wagner; W H Günzburg
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

4.  Exogenous Mtv-7 superantigen transgene expression in major histocompatibility complex class II I-E- mice reconstituted with embryonic stem cell-derived hematopoietic stem cells.

Authors:  C A Chambers; J Kang; J Pawling; B Huber; N Hozumi; A Nagy
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

5.  Generation of a tumorigenic milk-borne mouse mammary tumor virus by recombination between endogenous and exogenous viruses.

Authors:  T V Golovkina; I Piazzon; I Nepomnaschy; V Buggiano; M de Olano Vela; S R Ross
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

6.  The mouse mammary tumor virus envelope gene product is required for superantigen presentation to T cells.

Authors:  T V Golovkina; A Chervonsky; J A Prescott; C A Janeway; S R Ross
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.